Evolent Health, Inc.
Simbols: EVH
NYSE
31.93
USDTirgus cena šodien
-27.2314
P/E koeficients
0.0238
PEG koeficients
3.69B
MRK Cap
- 0.00%
DIV ienesīgums
Evolent Health, Inc. (EVH) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 677.41 | 192.8 | 188.2 | 266.3 | ||||||||||||
balance-sheet.row.short-term-investments | 118.9 | 13.8 | 14.5 | 75.7 | ||||||||||||
balance-sheet.row.net-receivables | 1480.17 | 446.7 | 254.7 | 130.6 | ||||||||||||
balance-sheet.row.inventory | -816.51 | 0 | -415.9 | -308.2 | ||||||||||||
balance-sheet.row.other-current-assets | 1020.3 | 30.3 | 451.1 | 435.3 | ||||||||||||
balance-sheet.row.total-current-assets | 2375.14 | 683.7 | 478.1 | 524 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 431.5 | 90.2 | 136.9 | 131.6 | ||||||||||||
balance-sheet.row.goodwill | 4469.59 | 1116.5 | 722.8 | 426.3 | ||||||||||||
balance-sheet.row.intangible-assets | 3157.46 | 752 | 442.8 | 279.8 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 7627.04 | 1868.6 | 1165.6 | 706.1 | ||||||||||||
balance-sheet.row.long-term-investments | 18.13 | 4.9 | 4.5 | 5.5 | ||||||||||||
balance-sheet.row.tax-assets | 25.53 | 12.1 | 0 | 39.4 | ||||||||||||
balance-sheet.row.other-non-current-assets | 108.87 | 20.9 | 32.3 | 13 | ||||||||||||
balance-sheet.row.total-non-current-assets | 8211.07 | 1996.6 | 1339.2 | 895.5 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 10586.21 | 2680.3 | 1817.3 | 1419.5 | ||||||||||||
balance-sheet.row.account-payables | 227.99 | 48.2 | 57.2 | 96.1 | ||||||||||||
balance-sheet.row.short-term-debt | 34.52 | 9.7 | 7.1 | 7.1 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 2596.52 | 635.1 | 469 | 273.4 | ||||||||||||
Deferred Revenue Non Current | 763.39 | 583.7 | 2.5 | 4.4 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 330.46 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 1593.18 | 610.3 | 363.4 | 330.4 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 3982.56 | 938.4 | 524.4 | 280.3 | ||||||||||||
balance-sheet.row.other-liabilities | 343.45 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 222.04 | 47.7 | 63.1 | 64.8 | ||||||||||||
balance-sheet.row.total-liab | 6207.46 | 1612.6 | 957.9 | 725.8 | ||||||||||||
balance-sheet.row.preferred-stock | 1695.41 | 178.4 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 345.76 | 1.2 | 1 | 0.9 | ||||||||||||
balance-sheet.row.retained-earnings | -2691.57 | -719.2 | -606.2 | -626.8 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -4.76 | -1.3 | -1.2 | -0.4 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5033.92 | 1608.6 | 1465.7 | 1319.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 4378.76 | 1067.7 | 859.4 | 693.6 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 10586.21 | 2680.3 | 1817.3 | 1419.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 4378.76 | 1067.7 | 859.4 | 693.6 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 10586.21 | - | - | - | ||||||||||||
Total Investments | 119.15 | 4.9 | 19 | 5.5 | ||||||||||||
balance-sheet.row.total-debt | 2626.43 | 644.8 | 476.1 | 280.5 | ||||||||||||
balance-sheet.row.net-debt | 1949.02 | 452 | 287.9 | 14.2 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -113.04 | -113 | -19.2 | -37.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 125.7 | 123.4 | 67.2 | 60 | |||||||||||
cash-flows.row.deferred-income-tax | -97.46 | -31.3 | 0.3 | -0.5 | |||||||||||
cash-flows.row.stock-based-compensation | 40.5 | 40.5 | 34 | 16.7 | |||||||||||
cash-flows.row.change-in-working-capital | 67.77 | 21.9 | -104.4 | -13.6 | |||||||||||
cash-flows.row.account-receivables | -164.69 | -164.7 | -103 | -5.8 | |||||||||||
cash-flows.row.inventory | 0 | -10.7 | 0 | -14.1 | |||||||||||
cash-flows.row.account-payables | -6.72 | -6.7 | 13.2 | 7.3 | |||||||||||
cash-flows.row.other-working-capital | 232.94 | 204.1 | -14.6 | -1 | |||||||||||
cash-flows.row.other-non-cash-items | 119.11 | 101.1 | 10.5 | 13.8 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 142.58 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -28.75 | -28.7 | -38.4 | -25 | |||||||||||
cash-flows.row.acquisitions-net | -388.25 | 0.9 | 5.6 | -34.8 | |||||||||||
cash-flows.row.purchases-of-investments | 387.45 | -0.9 | -5.6 | -3 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0.87 | 0.9 | 5.6 | 0.5 | |||||||||||
cash-flows.row.other-investing-activites | -387.74 | -387.7 | -226.3 | 46.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -415.54 | -415.5 | -259.1 | -15.8 | |||||||||||
cash-flows.row.debt-repayment | -464.47 | -464.2 | -219.7 | -98.8 | |||||||||||
cash-flows.row.common-stock-issued | 7.6 | 479.5 | 4.5 | 13.3 | |||||||||||
cash-flows.row.common-stock-repurchased | -15.29 | -15.3 | -18.3 | -3.9 | |||||||||||
cash-flows.row.dividends-paid | -18.79 | -18.8 | -14.9 | -1.3 | |||||||||||
cash-flows.row.other-financing-activites | 772.29 | 300.1 | 380 | 61.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 281.34 | 281.3 | 131.5 | -29.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.08 | -0.1 | -0.7 | -0.1 | |||||||||||
cash-flows.row.net-change-in-cash | 8.3 | 8.3 | -139.8 | -6.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 847.52 | 223.5 | 215.2 | 354.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 839.23 | 215.2 | 354.9 | 361.6 | |||||||||||
cash-flows.row.operating-cash-flow | 142.58 | 142.6 | -11.6 | 38.7 | |||||||||||
cash-flows.row.capital-expenditure | -28.75 | -28.7 | -38.4 | -25 | |||||||||||
cash-flows.row.free-cash-flow | 113.84 | 113.8 | -49.9 | 13.8 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1963.9 | 1963.9 | 1352 | 908 | ||||||||||||
income-statement-row.row.cost-of-revenue | 1503.43 | 1503.4 | 1035.4 | 657.6 | ||||||||||||
income-statement-row.row.gross-profit | 460.47 | 460.5 | 316.6 | 250.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 26.7 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 360.23 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34955.47 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 33.15 | -62.5 | 67.2 | 60 | ||||||||||||
income-statement-row.row.operating-expenses | 481.52 | 481.5 | 336.5 | 279.5 | ||||||||||||
income-statement-row.row.cost-and-expenses | 1984.95 | 1985 | 1371.9 | 937.1 | ||||||||||||
income-statement-row.row.interest-income | 5.26 | 5.3 | 1.4 | 0.4 | ||||||||||||
income-statement-row.row.interest-expense | 54.2 | 54.2 | 15.6 | 25.4 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34955.47 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -144.24 | -132.4 | -2.2 | -60 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 33.15 | -62.5 | 67.2 | 60 | ||||||||||||
income-statement-row.row.total-operating-expenses | -144.24 | -132.4 | -2.2 | -60 | ||||||||||||
income-statement-row.row.interest-expense | 54.2 | 54.2 | 15.6 | 25.4 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 58.49 | 123.4 | 67.2 | 60 | ||||||||||||
income-statement-row.row.ebitda-caps | 46.38 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -62.64 | -71.2 | -59.8 | 30.2 | ||||||||||||
income-statement-row.row.income-before-tax | -202.41 | -202.4 | -62.1 | -29.8 | ||||||||||||
income-statement-row.row.income-tax-expense | -89.36 | -89.4 | -43.4 | 0.5 | ||||||||||||
income-statement-row.row.net-income | -113.04 | -113 | -18.7 | -30.3 |
Biežāk uzdotie jautājumi
Kas ir Evolent Health, Inc. (EVH) kopējie aktīvi?
Evolent Health, Inc. (EVH) kopējie aktīvi ir 2680308000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 1067070000.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.234.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 1.002.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -0.058.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.032.
Kāda ir Evolent Health, Inc. (EVH) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -113040000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 644796000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 481525000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 192825000.000.